Home About Login Current Archives Announcements Editorial Board
Submit Now For Authors Call for Submissions Statistics Contact
Home > Archives > Volume 16, No 1 (2018) > Article

DOI: 10.14704/nq.2018.16.1.1148

A Pilot Study of F-18 FP-CIT PET Imaging in Early-onset Patients with Parkinson’s Disease: Parkin versus Non-parkin Mutation

Kyum-Yil Kwon, Seong-Beom Koh


Striatal dopaminergic dysfunction in early-onset Parkinson’s disease (PD) remains to be further elucidated. Thus, as a preliminary study, we aimed to investigate detailed patterns of dopaminergic depletion in five early-onset PD patients with dynamic N-(3-[(18) F]fluoropropyl)-2-carbomethoxy-3-(4-iodophenyl) nortropane (FP-CIT) positron emission tomography (PET) scans. Two patients with parkin mutation showed more symmetric decrease of dopamine transporter (DAT) density in the putamen, whereas others displayed asymmetric reduction of DAT density in the putamen. Notably, only those with parkin mutation revealed more severe dopaminergic deficits in the anteroventral putamen rather than the posterodoral putamen. Our observation suggests, among PD patients, patients with parkin mutation may exhibit the different pattern of striatal dopaminergic depletion.


Parkinson’s Disease, Early-Onset, Dopamine Depletion, Parkin Mutation

Full Text



Booij J, Tissingh G, Boer GJ, Speelman JD, Stoof JC, Janssen AG, Wolters EC, Van Royen EA. [123I] FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. Journal of Neurology, Neurosurgery & Psychiatry 1997;62(2):133-40.

Brooks DJ, Piccini P. Imaging in Parkinson’s disease: the role of monoamines in behavior. Biological Psychiatry 2006;59(10):908-18.

Broussolle E, Lücking CB, Ginovart N, Pollak P, Remy P, Dürr A, French Parkinson’s Disease Genetics Study Group. [18F]-dopa PET study in patients with juvenile-onset PD and parkin gene mutations. Neurology 2000;55(6):877-79.

Cummings JL, Henchcliffe C, Schaier S, Simuni T, Waxman A, Kemp P. The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration. Brain 2011;134(11):3146-66.

Hauser RA, Grosset DG. [123I] FPâ€CIT (DaTscan) SPECT Brain ımaging in patients with suspected Parkinsonian syndromes. Journal of Neuroimaging 2012;22(3):225-30.

Hu M, Scherfler C, Khan NL, Hajnal JV, Lees AJ, Quinn N, Wood NW, Brooks DJ. Nigral degeneration and striatal dopaminergic dysfunction in idiopathic and parkinâ€linked Parkinson's disease. Movement Disorders 2006;21(3):299-305.

Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. Journal of Neurology, Neurosurgery & Psychiatry 1992;55(3):181-84.

Jennings DL, Seibyl JP, Oakes D, Eberly S, Murphy J, Marek K. (123I) β-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in parkinsonian syndrome: unmasking an early diagnosis. Archives of Neurology 2004;61(8):1224-29.

Kane LA, Youle RJ. PINK1 and Parkin flag Miro to direct mitochondrial traffic. Cell 2011;147(4):721-23.

Khan NL, Graham E, Critchley P, Schrag AE, Wood NW, Lees AJ, Bhatia KP, Quinn N. Parkin disease: a phenotypic study of a large case series. Brain 2003;126(6):1279-92.

Lücking CB, Dürr A, Bonifati V, Vaughan J, De Michele G, Gasser T, Harhangi BS, Meco G, Denèfle P, Wood NW, Agid Y. Association between early-onset Parkinson's disease and mutations in the parkin gene. New England Journal of Medicine 2000;342(21):1560-67.

Madras BK, Gracz LM, Fahey MA, Elmaleh D, Meltzer PC, Liang AY, Stopa EG, Babich J, Fischman AJ. Altropane, a SPECT or PET imaging probe for dopamine neurons: III. Human dopamine transporter in postmortem normal and Parkinson's diseased brain. Synapse 1998;29(2):116-27.

Portman AT, Giladi N, Leenders KL, Maguire P, Veenma–van der Duin L, Swart J, Pruim J, Simon ES, Hassin–Baer S, Korczyn AD. The nigrostriatal dopaminergic system in familial early onset parkinsonism with parkin mutations. Neurology 2001;56(12):1759-62.

Ribeiro MJ, Thobois S, Lohmann E, Du Montcel ST, Lesage S, Pelissolo A, Dubois B, Mallet L, Pollak P, Agid Y, Broussolle E. A multitracer dopaminergic PET study of young-onset parkinsonian patients with and without parkin gene mutations. Journal of Nuclear Medicine 2009;50(8):1244-50.

Scherfler C, Khan NL, Pavese N, Eunson L, Graham E, Lees AJ, Quinn NP, Wood NW, Brooks DJ, Piccini PP. Striatal and cortical preâ€and postsynaptic dopaminergic dysfunction in sporadic parkinâ€linked parkinsonism. Brain 2004;127(6):1332-42.

Seibyl JP, Marchek KL, Quinlan D, Sheff K, Zoghbi S, Zeaâ€Ponce Y, Baldwin RM, Fussell B, Smith EO, Charney DS, Hoffer PB. Decreased singleâ€photon emission computed tomographic {123I} βâ€CIT striatal uptake correlates with symptom severity in parkinson's disease. Annals of Neurology 1995;38(4):589-98.

Thobois S, Guillouet S, Broussolle E. Contributions of PET and SPECT to the understanding of the pathophysiology of Parkinson’s disease. Neurophysiologie Clinique/Clinical Neurophysiology 2001;31(5):321-40.

Thobois S, Ribeiro MJ, Lohmann E, Dürr A, Pollak P, Rascol O, Guillouet S, Chapoy E, Costes N, Agid Y, Remy P. Young-onset Parkinson disease with and without parkin gene mutations: a fluorodopa F 18 positron emission tomography study. Archives of Neurology 2003;60(5):713-18.

Varrone A, Pellecchia MT, Amboni M, Sansone V, Salvatore E, Ghezzi D, Garavaglia B, Brice A, Brunetti A, Bonavita V, De Michele G. Imaging of dopaminergic dysfunction with [123I] FP-CIT SPECT in early-onset parkin disease. Neurology 2004;63(11):2097-103.

Wang J, Hoekstra JG, Zuo C, Cook TJ, Zhang J. Biomarkers of Parkinson's disease: current status and future perspectives. Drug Discovery Today 2013;18(3):155-62.